文献速递乳房整形与再造美容整形创面修复

色甘酸钠、孟鲁司特与扎鲁司特预防包膜挛缩的比较

Comparison of Cromolyn Sodium, Montelukast, and Zafirlukast Prophylaxis for Capsular Contracture.
PubMed 文献 · Plast Reconstr Surg · 2022-08-22

该研究将30只雌性Wistar白化大鼠随机分为对照组、假手术组、色甘酸钠组、孟鲁司特组和扎鲁司特组,术前1个月开始每日腹腔注射,植入微型乳房植入物后继续注射3个月,取包膜行组织病理学评估。结果显示三种药物组的急性炎症、炎症严重程度评分、异物反应、肥大细胞计数和包膜厚度均低于对照组和假手术组(p<0.05),且色甘酸钠组上述参数优于孟鲁司特组和扎鲁司特组(p<0.05)。结论认为色甘酸钠抑制包膜挛缩似乎比孟鲁司特和扎鲁司特更有效。

要点

  • 大鼠模型中色甘酸钠、孟鲁司特和扎鲁司特均降低包膜急性炎症、异物反应、肥大细胞计数和包膜厚度(p<0.05)。
  • 色甘酸钠组上述组织病理学参数优于孟鲁司特组和扎鲁司特组(p<0.05)。
  • 作者认为色甘酸钠预防包膜挛缩似乎比孟鲁司特和扎鲁司特更有效。

核心结论

  • 色甘酸钠似乎比孟鲁司特和扎鲁司特更有效地抑制包膜挛缩。
  • 本报告可能是色甘酸钠预防包膜挛缩的先驱研究。

研究设计与样本

  • 30只雌性Wistar白化大鼠随机分为五组:对照组、假手术组、色甘酸钠组、孟鲁司特组和扎鲁司特组。
  • 假手术组每日腹腔注射1 ml,色甘酸钠组每日10 mg/kg,孟鲁司特组每日10 mg/kg,扎鲁司特组每日1.25 mg/kg,术前1个月开始给药。
  • 各组大鼠背部放置微型乳房植入物,注射持续3个月后处死大鼠,取包膜行组织病理学评估。

主要发现

  • 色甘酸钠组、孟鲁司特组和扎鲁司特组的急性炎症、平均炎症严重程度评分、异物反应发生率、肥大细胞计数和包膜厚度均低于对照组和假手术组(p<0.05)。
  • 色甘酸钠组上述参数优于孟鲁司特组和扎鲁司特组(p<0.05)。

临床怎么用

  • 作者认为色甘酸钠预防包膜挛缩似乎比孟鲁司特和扎鲁司特更有效。
  • 本报告可能是色甘酸钠预防包膜挛缩的先驱研究。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Capsular contracture is the most common complication following breast augmentation. Recently, prophylaxis studies aiming to inhibit the release of profibrotic substances to prevent capsular contracture have gained in importance. This study investigated the effects of cromolyn sodium, montelukast, and zafirlukast on capsular contracture in a rat model. METHODS: Thirty female Wistar albino rats were randomly divided into five groups: control, sham, cromolyn sodium, montelukast, and zafirlukast. Intraperitoneal injections were administered daily to the sham (1 ml per day), cromolyn sodium (10 mg/kg per day), montelukast (10 mg/kg per day), and zafirlukast (1.25 mg/kg per day) groups 1 month before surgery. Miniature breast implants were then placed on the backs of the rats in each group. Injections were continued for the next 3 months. The rats were subsequently killed, and the capsules were harvested and assessed histopathologically. The histopathologic outcomes were acute inflammation status, inflammation severity, synovial metaplasia, foreign body reaction, mast cell count, and capsular thickness. RESULTS: The cromolyn sodium, montelukast, and zafirlukast groups had less acute inflammation and lower mean inflammation severity scores, foreign body reaction occurrence, mast cell counts, and capsular thickness than the control and sham groups ( p < 0.05). These parameters were better in the cromolyn sodium group than in the montelukast and zafirlukast groups ( p < 0.05). CONCLUSIONS: Cromolyn sodium appears to inhibit capsular contracture more efficiently than montelukast and zafirlukast. This report may be a pioneer study for the prophylactic use of cromolyn sodium in capsular contracture. CLINICAL RELEVANCE STATEMENT: The prophylactic administration of cromolyn sodium appears to reduce capsular contracture more efficiently than that of montelukast and zafirlukast. This report might constitute a pioneer study for the prophylactic use of cromolyn sodium in capsular contracture.

来源:Plast Reconstr Surg,查看原文。版权归原作者所有。

引用

  1. Menkü Özdemir FD, Üstün GG, Kősemehmetoğlu K, et al. Comparison of Cromolyn Sodium, Montelukast, and Zafirlukast Prophylaxis for Capsular Contracture. Plast Reconstr Surg. 2022. PMID: 35994348. doi:10.1097/PRS.0000000000009653

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。